canertinib has been researched along with leflunomide in 2 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (leflunomide) | Trials (leflunomide) | Recent Studies (post-2010) (leflunomide) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 1,725 | 173 | 659 |
| Protein | Taxonomy | canertinib (IC50) | leflunomide (IC50) |
|---|---|---|---|
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Mus musculus (house mouse) | 0.03 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.5 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 4.63 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 4.63 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.884 | |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | 5.4 | |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Rattus norvegicus (Norway rat) | 0.009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
2 other study(ies) available for canertinib and leflunomide
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |